A Study of NGM621 in Participants With Geographic Atrophy

  • End date
    Apr 12, 2023
  • participants needed
  • sponsor
    NGM Biopharmaceuticals, Inc
Updated on 29 August 2021
geographic atrophy
macular degeneration


This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

Condition Dry Macular Degeneration, age-related macular degeneration, Macular Degeneration, Geographic Atrophy
Treatment Sham comparator, NGM621
Clinical Study IdentifierNCT04465955
SponsorNGM Biopharmaceuticals, Inc
Last Modified on29 August 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note